Breaking into Merck's CCK Patents: the Starting Point of PNB Vesper Life Science to Design and Develop Cholecystokinin(CCK)-Antagonists as Targeted Chemotherapeutics
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.